Editorial & Columns Revenue, EBITDA and Market Capitalisation: Linkage in Valuation of Pharma Companies in India June 11, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY25 Review: Profitability of Leading Pharma Companies in India May 28, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Joint Ventures: Experience of Indian Pharmaceutical Companies May 21, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY24 Review: Profitability of select Pharmaceutical Companies in India April 9, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Insider or an Outsider as a CEO: Insights on Pharmaceutical Industry in India March 20, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns On the Right Side of Regulations: The USFDA and Indian Pharmaceutical Companies March 12, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns CSR by Pharmaceutical Companies and Engagement with SHGs, NGOs & Foundations March 6, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Patent Cliff: Opportunity for Indian Pharmaceutical Companies February 27, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Product Portfolio of Top Indian Pharmaceutical Companies January 15, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY24 Review: Attrition and Employee Turnover in Top Indian Pharmaceutical Companies January 2, 2025 | Dr. Anil Kumar Angrish | No Comments | More